Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink

Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success

Leerink Partners analyst Geoffrey Porges reduced Aducanumab probability of success and cut his price target on Biogen (NASDAQ: BIIB) price target of $355.00 (from $365.00) after Lilly announced on Wednesday that the EXPEDITION 3 study of solanezumab (sola) in mild Alzheimer's patients did not meet its primary or secondary... More

Eli Lilly (LLY) PT Cut to $92 at Leerink Partners

Leerink Partners analyst Seamus Fernandez lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $102.00) following the Sola failure but maintains a Outperform rating.

Fernandez commented, "LLY announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION 3 study. Per our follow up... More

BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure

BMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).

Analyst Alex Arfaei commented, "We believe Solas failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lillys long-term growth... More

Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird

Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the company.,

Skorney commented, "Lilly's registrational EXPEDITION 3 trial for solanezumab in mild Alzheimer's patients failed. Though some secondary endpoints favored sola, Lilly's admission that... More

Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness

Mizuho analyst Salim Syed weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly announced this morning that its Alzheimer's drug, Solanezumab Phase 3 study has failed and it will not pursue approval which has implications to Biogen's Aducanumab.

Syed commented, "While we are... More

Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital

BMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.

Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failure, as we... More

Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.

Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure

Biogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).